P2-241: Plasma testosterone levels and cognitive function in borderline hypogonadal older men

Abstract

disease (cerebral, cardiac or peripheral arterial disease). These VRF were considered present according to history, medication used, examination or laboratory results at the first standardised evaluation. They were considered treated if they received, respectively, an antihypertensive, an oral antihyperglycemic or insulin, a statin or a fibrate, an antiplatelet or an anticoagulant. Preliminary Results: Among the first 406 patients included (approximately 57% of the whole cohort), 377 (92.1%) had at least one VRF. Only 121 (32.1%) had all their VRF treated (treated group). We compared them with the 83 (22%) who had none of their VRF treated (untreated group). Both groups were similar for age (73.1 years), sex distribution (62.6% women), educational level (76.5% lower level), baseline MMSE (21.7), final diagnosis (60.1% AD), acetyl-cholinesterase inhibitors utilization (67%), and follow-up length (3.5 years). MMSE evolution over time was compared between treated and untreated groups with a mixed model adjusted for age, sex, education, first MMSE, diagnosis and year of first visit. Overall, MMSE decline is significantly slower in the treated group (p 0.003, figure 1). For pure AD cases (n 128), a similar trend emerges but does not reach statistical significance (p 0.073, figure 2).